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STROKE IN PATIENTS WITH SICKLE CELL DISEASE
Clinical and neurological aspects
Carolina Camargo de Oliveira1, Sylvia Maria Ciasca2, M. Valeriana L. Moura-Ribeiro3
Abstract – The aim of this study was to characterize a group of patients (n=8) with sickle cell disease (SCD) and 
ischemic stroke concerning the clinical, neurological, imaging and progressive aspects. Data were collected 
from records and completed with an interview of patients and their parents. In this study there were 8 
patients with ages ranging from 10 to 23 years old; SCD diagnosis was given between one and two years 
of age with clinical features of fatigue and anemia. The stroke was ischemic in all individuals and the first 
cerebrovascular event occurred before 6 years of age; 3 patients had recurrence of stroke despite prophylactic 
blood transfusion therapy and both cerebral hemispheres were affected in 4 patients. Clinical and neurological 
current features observed were: acute pain crises, sialorrhea, mouth breathing, motor, and neuropsychological 
impairments resulting from cortical-subcortical structure lesions.
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Acidente cerebrovascular em pacientes com anemia falciforme: aspectos clínicos e neurológicos
Resumo – O objetivo deste estudo foi caracterizar um grupo de sujeitos (n=8) com antecedentes de anemia 
falciforme (AF) e acidente vascular cerebral (AVC) isquêmico, dos pontos de vista clínico, neurológico, 
radiológico e evolutivo, reavaliados através de exame neurológico e neuropsicológico. A partir de prontuários 
dos sujeitos com diagnóstico comprovado de AF e AVC, coletamos dados, complementados por entrevista com 
pacientes e responsáveis. Foram avaliados 8 pacientes; atualmente com idades entre 10 e 23 anos; diagnóstico 
da AF entre um e dois anos; quadro clínico de fraqueza e anemia. Em todos, o AVC foi isquêmico e o primeiro 
evento na maioria ocorreu antes dos 6 anos de idade; houve recorrência do AVC em 3, apesar da profilaxia com 
transfusão sanguínea; ambos os hemisférios afetados em 4; no quadro clínico e neurológico atual constatamos 
crises dolorosas, sialorréia, respiração oral e importante comprometimento motor e neuropsicológico, 
resultantes de lesões estruturais cortico-subcorticais.
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Stroke is 221 to 300 times more frequent in patients 
with sickle cell disease (SCD) when compared to healthy 
children1,2, occurring in approximately 11% of homozygote 
individuals (SS) under the age of 203, with a prevailing inci-
dence between four and 15 years of age2,4. The cerebrovas-
cular event may be devastating in 7% of the children with 
SCD, with a possibility of new episodes (0,7% per year) 
during the first twenty years of life. The episodes appear 
isolated or associated with infection, dehydration, acute 
pain crisis, aplastic crises, priapism, among others3,5. A re-
search involving 42 children with asymptomatic SCD and 
normal neurological clinical exam revealed that, among all 
hematimetric parameters and clinical indicators, the mean 
corpuscular volume was significantly risk predictive, and 
the magnetic resonance image (MRI) was an important re-
source of image, detecting cerebrovascular abnormalities 
in asymptomatic patients caused by ischemia in territory 
of the middle cerebral artery and perforating branches6.
A study with 146 patients found that in older ages it 
is usual the involvement of large vessels by stenosis or 
occlusion with consequent encephalomalacia. In young-
er ages, small vessels impairment predominates, with cys-
tic fibrosis probably of embolic cause. In decrescent or-
der, effects were more evident in the white matter, cau-
date, putamen, and thalamus particularly involving the re-
gion of lenticulostriate arteries7. In a retrospective study, 
researchers compared a group of 14 children with SCD 
and stroke to another group of SCD children without any 
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cerebrovascular event. In order to highlight the physical 
and cognitive effects of the vascular events, the individ-
uals were evaluated with Motor Assessment Scale, Barthel 
Index, WISC, California Test of Personality and Test of Lan-
guage Development. Patients of the experimental group 
were physically independent, with a slight or no motor 
deficit of postural acquisitions; however, they presented 
moderate to severe dysfunction in hand motor function 
(42%); intellectual deficits; severely impaired speech; dis-
orders in psychosocial adjustment8.
The aim of this study was to characterize a group of 
patients (n=8) with SCD and ischemic stroke, concerning 
the clinical, neurological, imaging and progressive (neuro-
logical and neuropsychological) aspects. This study is part 
of a larger project involving a prospective evaluation of 
SCD patients with and without cerebrovascular events.
METHOD
After the project approval by the Ethical Committee on Re-
search of FCM/UNICAMP, 22 patients with SCD and age ranging 
from 5 to 25, who receive specific clinical and hematological at-
tendance at Ambulatories of HC/UNICAMP, were pre-selected. 
After analysis of the records, 8 patients with SCD and clinical 
stroke validated by hematological tests and neurological imag-
ing were selected. These patients attended the Ambulatory for 
Research of Cerebrovascular Disease of the Faculdade de Ciên-
cias Médicas (FCM/UNICAMP).
Patients and their parents were informed about the research 
objectives and procedures and agreed to participate by signing 
a Free Consent Agreement Form. A protocol was organized in-
cluding identification data, neurological clinical exam, neuro-
psychological assessment, laboratorial and neurological imag-
ing screening; data were collected from records and completed 
with an interview of patients and their parents.
RESULTS
Table 1 presents the identification data (gender, col-
or, age when SCD was diagnosed, SCD initial clinical signs 
and age at present study).
Five patients were female; six patients had brown skin 
color and two were black; the SCD diagnosis was screened 
before the first year of age in two patients, between one 
and two years in five patients and at five years in one. The 
initial clinical signs were fatigue, pallor and the first stroke 
in three patients; jaundice, dehydration and acute pain cri-
sis in two; syncope in one patient. The age of the patients 
during the present study ranged from 10 to 23 years old.
Table 2 presents data related to cerebrovascular event 
(age at stroke; type; number of events; impaired brain hemi-
sphere; arterial territory; and neurological imaging exam).
It was observed that the first stroke occurred before 
two years of age in three children, patient 4 presented a 
second stroke during the evolution; between two and six 
years of age, stroke occurred in two; between seven and 10 
years of age it occurred in two patients, with recurrence 
for case 3; and above 10 years of age, in one. The cerebro-
vascular events were ischemic in all patients; two patients 
presented clinical evidences of transient ischemic attacks 
(TIA) with radiological and therapeutical procedures. Both 
brain hemispheres were affected in six patients; the left 
hemisphere in one, and the right hemisphere in another. 
The arterial territory affected was that of the middle ce-
rebral artery (MCA) and perforating branches, anterior ce-
rebral artery (ACA), posterior cerebral artery (PCA), and 
superior cerebral artery (SCA).
Table 3 depicts data relating to the treatment of the 
patients; to their general clinical signs at present study; the 
neurological exam of the acute stroke period (I) and the 
neurological exam at the present study (II) conducted be-
tween 2 and 13 years after the last cerebrovascular event.
Seven patients maintain a chronic transfusion thera-
py for secondary prophylaxy and use of desferrioxamine. 
The clinical features observed at present study were: he-
mosiderosis in eight patients; snores and pain crises in 
three; sialorrhea in two; jaundice in one and cardiac mur-
mur in another patient. Mouth breathing was found in sev-
en patients (except on case 6). During the acute period 
after stroke the neurological exam revealed hemiparesis 
Table 1. Identification data of and related to SCD diagnosis.
Patients Gender Color Age* Clinical signs** Current age
1 F Brw 3 m jaundice 10 y
2 F Brw 1 y 6 m dehydration   pain crisis   stroke 15 y
3 F Brw 1 y 8 m dehydration 23 y
4 F Brw 1 y pain crisis   stroke 12 y
5 F B 1 y 2 m fatigue   pallor   syncope 19 y
6 M Brw 8 m fatigue   pallor   jaundice 16 y
7 M Brw 1 y fatigue   pallor   17 y
8 M B 5 y stroke 12 y
SCD, sickle cell disease; *age at SCD diagnosis; **clinical signs of SCD diagnosis; F, female; M, male; Brw, brown; 
B, black; y, years; m, months.
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in seven patients; neuropsychomotor delay, visual deficit 
and seizure in two; each of the following symptoms was 
found in one patient: paresthesia; rhyme deviation; apha-
sia and dysphagia. In the present neurological exam it was 
assessed spastic hemiparesis in six patients (two with bi-
lateral assimetric hypertonia), mental deficiency in four 
and visual deficit in two. Mental deficiency was detected 
by previously applied neuropsychologic test (WISC) and 
present clinical neurologic exam.
All patients received therapeutic orientation except 
for patient 2; hemosiderosis was found in eight patients 
in addition to other events such as acute pain crises, snore 
and sialorrhea, among others. Neurological exam I dem-
onstrated hemiparesis in seven patients and neuropsycho-
motor delay in two patients. The neurological exam of the 
present research indicates that the uni or bilateral struc-
ture lesions in frontal, parietal, occipital, and cerebellum 
areas persist, according to the analysis of Tables 2 and 3.
DISCUSSION
In a study with 3647 patients with SCD it was found 
a predominance of ischemic cerebral events in individu-
Table 2. SCD and stroke, general data and neurological imaging.
Patient Age * Type N Hemisphere Arterial region Neuro-imaging (ed)
1 9m I stroke 1 L  R SCA  PCA bilat CT (11/95)
CT (7/97)
2 1y 6m I stroke 1 L MCA L CT (2/91)
3 8y 12y
13y
I stroke 4 L  R MCA  ACA bilat
PCA R
CT (89)   CT 
(9/94) CT (95)










5 11y I stroke 1 L  R MCA  PCA L
ACA R
CT (7/97)











8 5y I stroke 1 L  R MCA  ACA  PCA  
BN L      ACA R
CT (12/98)
SCD, sickle cell disease; *at stroke; **clinical evidence; I stroke, ischemic cerebrovascular event; TIA, transient ischemic attack; L, 
left; R, right; SCA, superior cerebellar artery; PCA, posterior cerebral artery; bilat., bilateral; MCA, middle cerebral artery; ACA, 
anterior cerebral artery; PB, perforating branches; BN, basal nucleus; ed, exam date; CT, cranial tomography; SPECT, single pho-
ton emission computed tomography.
Table 3. SCD and stroke, clinical sign and neurological exams I and II.
Patients Treatment Clinical Sign Neurol Exam I Neurol Exam II
1 Blood transf
desferrioxamine
HMS NPMR  Hp R
VD
global hypot  VD
MD
2 ___ HMS pain crisis
jaundice
NPMR  Hp R
VD




HMS sialorrhea Hp L  S  aphasia Hp L   aphasia
MD
4 Blood transf 
desferrioxamine




snore  heart murmur
Hp R Hp R
6 Blood transf
desferrioxamine
HMS pain paresth L 
hand rhyme deviation
Hp R  





Hp R  dysphagia hypot L
8 Blood transf
desferrioxamine
HMS sialorrhea Hp R  S Hp R   aphasia
MD
SCD, sickle cell disease; Neurol Ex I, at hospital discharge; Neurol Ex II, at present study; Blood transf, regular blood transfusion; 
HMS, hemosiderosis; NPMR, neuropsychomotor retardation; Hp, hemiparesis; R, right; L, left; hypot, hypotonia; hypert, hyper-
tonia; VD, visual deficiency; S, seizure; MD, mental deficiency; paresth, paresthesia; ___, without information.
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als under 20 and above 29 years old and of hemorrhagic 
events in the group between 20 and 29 years of age, which 
determined a larger number of deaths (26%) in the latter2.
In the present study, it was observed a predominance 
of brown skin female and SCD diagnosis under two years 
of age. Despite the low number of individuals evaluated, 
findings are in accordance with data of references, evi-
dencing patients with SCD and stroke in early age, all with 
ischemic event. There was bilateral hemisphere involve-
ment by stroke in six patients, with recurrence in two and 
a single event in four patients.
Neuropsychomotor development in SCD children was 
considered normal until three years of age with progres-
sive performance decay in neuropsychological and motor 
function tests due to ischemic cerebral insults and/or si-
lent infarct9. Similar findings was observed in this present 
study. The psychomotor function was intact and an early 
decay of cognitive functions was detected in SCD children 
between 12 and 24 months of age10. Children with SCD 
and ischemic stroke usually present motor deficits, apha-
sia, learning difficulties and cognitive impairment, and it 
seems that silent infarcts are the main cause of cerebral 
insults causing learning disorders, low intelligence quo-
tient and other neurocognitive deficits6,11.
Most of our patients presented vascular event after 
four years of age and had apparently adequate neuro-
psychomotor development until the stroke. The present 
neurological exam evidenced important neurological se-
quelae: motor deficit in eight patients; mental deficiency 
in four; aphasia and visual deficit in two patients. Through-
out the assessment, we observed lack of initiative, dif-
ficulty to understand the clinical neurologic assessment 
and slowness in motor and speech responses.
Chronic transfusion therapy has been indicated as pro-
phylaxis for the cerebrovascular event recurrence since 
1976 by Lusher et al.12. Unfortunately, stroke risk returns 
once the transfusion scheme is interrupted. Recent stud-
ies revealed that such practice may decrease but does 
not eliminate totally the risk13. In a retrospective study, 
44 patients were evaluated in blood transfusion therapy 
after ischemic stroke. A high index of recurrence (41%) 
was observed and detected the presence of collaterals 
Moyamoya like (43%)14.
In this study, patients 3 and 4 presented stroke recur-
rence, even under prophylactic blood transfusion therapy. 
Both presented important motor and cognitive impair-
ments; patient 4 also presented TIA. Even though not 
being an objective of the study, mental deficiency was 
detected in quantitative tests in patients 1, 4 and 8, and 
qualitative mental deficiency was observed in patient 3. 
Among these cases, 3 and 8 presented higher impairment 
in the current neurological exam, suggesting a possibil-
ity of silent infarcts determining motor sequelae, mental 
deficiency and aphasia.
In summary, from the eight patients, seven received 
prophylactic blood transfusion therapy for stroke recur-
rence during at least five years. Three of them had no ben-
efit, progressing with stroke recurrence and neurological 
signs aggravation. The cases also revealed cerebrovascular 
event in younger ages and higher neurological impairment 
compared to literature data. Although not quantitatively 
analyzed, we observed important social-economic diffi-
culties, as well as family members low level of understand-
ing about SCD, its management and possible co-morbities. 
Such condition may have favored a lower adherence to 
treatment, thus increasing the probability of cerebrovas-
cular events and highly impairing sequelae.
In conclusion, the present study detected the SCD di-
agnostic in early age with ischemic stroke identified as 
the initial sign in three patients; high occurrence of isch-
emic cerebral event in children above four years of age; 
stroke and TIA recurrence in spite of secondary prophy-
lactic blood transfusion therapy; neuropsychological im-
pairment in our patients, identified by specific tests; and 
it was possible to find motor impairments resulting from 
cortical-subcortical structure lesions involving one brain 
hemisphere or both.
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